PET/CT using ¹⁸F-FDG is an essential part of the management of patients with lymphoma. Efforts to standardize PET acquisition and reporting, including the 5-point Deauville scale, have enabled PET to become a surrogate for treatment success or failure in common lymphoma subtypes. This review summarizes the key clinical-trial evidence that supports PET-directed personalized approaches in lymphoma. PET-guided therapy has improved outcomes in Hodgkin lymphoma, using less chemotherapy and more selective radiotherapy. Attempts to intensify chemotherapy in aggressive non-Hodgkin lymphomas have, however, proved ineffective in patients treated with rituximab and chemotherapy. Trials are under way to determine whether PET can obviate consolidation radiotherapy in patients with diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma. More recently, PET has been reported to be a reliable predictor of outcome in follicular lymphoma requiring treatment, and prospective trials to test PET-guided therapy in this disease are anticipated.

PET/CT 使用¹⁸F-FDG 是淋巴瘤患者管理的重要组成部分。标准化 PET 采集和报告的努力，包括 5 点多维尔量表，使 PET 成为常见淋巴瘤亚型治疗成功或失败的替代指标。本综述总结了支持 PET 导向的淋巴瘤个体化治疗的关键临床试验证据。PET 引导的治疗改善了霍奇金淋巴瘤的预后，使用更少的化学疗法和更多的选择性放射疗法。然而，在侵袭性非霍奇金淋巴瘤中加强化疗的尝试已证明对接受利妥昔单抗和化疗的患者无效。正在进行试验以确定 PET 是否可以避免对弥漫性大 B 细胞淋巴瘤和原发性纵隔 B 细胞淋巴瘤患者进行巩固放疗。最近，